Clinical trials: Hyperinsulinemia
Metabolic Syndrome
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
Primary objective: To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome Secondary objectives: To…
- Trial name
- VICTORIA (NCT00299325)
- Testing
- Rimonabant, Mild hypocaloric diet
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 254 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation
Insulin Resistance
Effects of Hi-maize Resistant Starch on Insulin Sensitivity
The purpose of this study is to determine the effects of a dietary fiber, resistant starch, on insulin sensitivity. Low insulin sensitivity is a risk factor for some diseases including type 2 diabetes and heart disease.
- Trial name
- NCT01058135
- Testing
- Hi-maize starch (Low dose), Hi-maize starch (High-dose), Control (starch)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ingredion Incorporated
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Glucose Homeostasis
Comparison of the Effects of a 12-Week Consumption of Two Carbonated Beverages on Insulin Sensitivity
The purpose of this study is to determine whether consumption of carbonated drinks containing sweeteners affect insulin sensitivity.
- Trial name
- SEDULC (NCT02031497)
- Testing
- Drink with sweeteners, Drink without sweeteners
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute For European Expertise in Physiology
Insulin Resistance
Impact of Starch Digestibility on Glycemic Variability and Control, Cardiometabolic and Inflammatory Profiles, Microbiota and Intestinal Health in Subjects With Insulin Resistance
To study the potential impact of a diet rich in both Slowly Digestible Starch (SDS) and Resistant Starch (RS), we propose a 2-month nutritional intervention study in which we will study the evolution of carbohydrate variability…
- Trial name
- GLYMICARE (NCT07408479)
- Testing
- Balanced diet high in Slowly Digestible Starch and Resistant Starch, Balanced diet low in Slowly Digestible Starch and Resistant Starch
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Menopause, Climacteric Syndrome
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
The study collected retrospective data from the assumption of combined natural molecules in menopausal women with metabolic syndrome
- Conditions
- Menopause, Climacteric Syndrome, Metabolic Syndrome
- Trial name
- NCT06057896
- Testing
- inositol, phytoestrogens, cocoa polyphenols
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lo.Li.Pharma s.r.l
Healthy
A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber
The objective of this trial is to evaluate the postprandial glucose and insulin responses to replacing digestible carbohydrates with resistant starch type 4 (RS4) in a baked product in healthy men and women.
- Trial name
- NCT03239288
- Testing
- Control digestible carbohydrate, Test resistant starch type 4
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cargill
Type 1 Diabetes
Transdermal Basal Insulin Patch Study in Type 1 Diabetes
This study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.
- Trial name
- NCT00519623
- Testing
- PassPort(R) Transdermal Insulin Delivery System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Altea Therapeutics
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Insulin Resistance
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
The present study on pharmacological intervention in autonomic nervous dysregulation(parasympathetic dysfunction,) regarding insulin resistance, is a concept testing in humans tohelp identify potential new pharmacological target…
- Trial name
- NCT00689208
- Testing
- Atropine, Physostigmine
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Metabolic Syndrome, Cardiac Fibrosis
The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis
The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis
- Trial name
- NCT05689710
- Testing
- Inositol and alpha-lactalbumin
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Lo.Li.Pharma s.r.l
Hyperlipidemia, Low-density-lipoprotein-type
Combined Effects of Bioactive Compounds in Lipid Profile
The aim of this study is to demonstrate whether, along with dietary recommendations, Armolipid Plus ® can improve the profile of patients with elevated plasma LDL-C acting as a change of lifestyle therapy (TLC) according to the…
- Conditions
- Hyperlipidemia, Low-density-lipoprotein-type, Elevated Triglycerides
- Trial name
- ARM-PLUS-LDL (NCT01562080)
- Testing
- Armolipid Plus
- Where
- Spain
- Volunteers
- 118 people
- Sponsor
- Rottapharm Spain
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, PreDiabetes
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease.
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
- Trial name
- TRANSFORM (NCT06112418)
- Testing
- The Cleerly CAD Staging System
- Where
- 125 sites in United States
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Cleerly, Inc.
Prehypertension, Elevated Blood Pressure
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure.
- Conditions
- Prehypertension, Elevated Blood Pressure, Blood Pressure, Metabolic Syndrome
- Trial name
- INSIGHT (NCT05469503)
- Testing
- TOTUM-854
- Where
- 10 sites in Bulgaria, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Valbiotis
Schizophrenia
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with…
- Trial name
- SWITCH (NCT04312503)
- Testing
- Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone
- Where
- 18 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Metabolic Cardiovascular Syndrome
Hyperinsulinemic Euglycemic Clamp Protocol
The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from…
- Trial name
- NCT01408667
- Testing
- TRC150094
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Torrent Pharmaceuticals Limited
Insulin Resistance
A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production
The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin…
- Trial name
- NCT00991107
- Testing
- HE3286
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Harbor Therapeutics